HRP20141149T1 - Dugotrajno lijeäśenje simptomatske sräśane insuficijencije - Google Patents
Dugotrajno lijeäśenje simptomatske sräśane insuficijencije Download PDFInfo
- Publication number
- HRP20141149T1 HRP20141149T1 HRP20141149AT HRP20141149T HRP20141149T1 HR P20141149 T1 HRP20141149 T1 HR P20141149T1 HR P20141149A T HRP20141149A T HR P20141149AT HR P20141149 T HRP20141149 T HR P20141149T HR P20141149 T1 HRP20141149 T1 HR P20141149T1
- Authority
- HR
- Croatia
- Prior art keywords
- pufa
- intended
- accordance
- fatty acids
- weight
- Prior art date
Links
- 238000011866 long-term treatment Methods 0.000 title 1
- 208000019270 symptomatic heart failure Diseases 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 150000004665 fatty acids Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940082657 digitalis glycosides Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229940124975 inotropic drug Drugs 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 210000000264 venule Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Magnetic Heads (AREA)
Claims (8)
1. n-3 PUFA, namijenjena upotrebi u liječenju simptomatskog HF kod pacijenata s istisnim udjelom lijeve klijetke < 40% (LVEF < 40%), dijabetesom i/ili ukupnim kolesterolom < 200 mg/dl, po mogućnosti ≤ 188 mg/dl, kako bi se smanjilo smrtnost ili hospitalizaciju zbog kardiovaskularnog uzroka, naznačena time što je n-3 PUFA smjesa masnih kiselina sa sadržajem EPA i DHA koji se kreće između 75% i 95%, težinski, na ukupnu težinu masnih kiselina, gdje se navedenu n-3 PUFA primjenjuje dulje od 3,5 godina na navedenim pacijentima.
2. n-3 PUFA, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je n-3 PUFA smjesa masnih kiselina sa sadržajem EPA i DHA od najmanje 85%, težinski, na ukupnu težinu masnih kiselina, a ukupni sadržaj n-3 PUFA je najmanje 90%, težinski, na ukupnu težinu masnih kiselina.
3. n-3 PUFA, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je n-3 PUFA smjesa etilnih estera EPA i DHA u omjeru koji se kreće između 0,9 i 1,5, sadržaj etilnog estera EPA se kreće između 40 i 51%, a sadržaj etilnog estera DHA se kreće između 34 i 45%, težinski, na ukupnu težinu masnih kiselina.
4. n-3 PUFA, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je doza n-3 PUFA koju treba primijeniti na pacijentu sa simptomatskim HF dnevna doza od 1 g oralno.
5. n-3 PUFA, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dodatno sadrži jedno ili više dodatnih sredstava namijenjenih primjeni u kombinaciji, i to bilo zajedno ili odvojeno, uglavnom istodobno ili uzastopno, s n-3 PUFA.
6. n-3 PUFA, namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačena time što se terapijsko sredstvo bira iz skupine koju čine: inhibitori ACE, inhibitori NEP, inhibitori ACE/NEP, inhibitori angiotenzin I-konvertirajućeg enzima, diuretici, pozitivno inotropni lijekovi, inhibitori fosfodiesteraze, vazodilatatori arteriola i venula, β-blokatori i glikozidi digitalisa, ili njihova smjesa.
7. n-3 PUFA, namijenjena upotrebi u skladu s patentnim zahtjevom 6, naznačena time što je terapijsko sredstvo statin.
8. n-3 PUFA, namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što se statin bira iz skupine koju čine: simvastatin, lovastatin, fluvastatin, pravastatin, atorvastatin, cerivastatin, rovastatin i rosuvastatin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161994 | 2008-08-07 | ||
| PCT/EP2009/005347 WO2010015335A1 (en) | 2008-08-07 | 2009-07-23 | Long-term treatment of symptomatic heart failure |
| EP09777388.1A EP2323647B1 (en) | 2008-08-07 | 2009-07-23 | Long-term treatment of symptomatic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141149T1 true HRP20141149T1 (hr) | 2015-02-13 |
Family
ID=40101155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141149AT HRP20141149T1 (hr) | 2008-08-07 | 2014-11-25 | Dugotrajno lijeäśenje simptomatske sräśane insuficijencije |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8592439B2 (hr) |
| EP (1) | EP2323647B1 (hr) |
| JP (1) | JP5563573B2 (hr) |
| KR (1) | KR20110058775A (hr) |
| CN (1) | CN102149376B (hr) |
| AU (1) | AU2009278317B2 (hr) |
| BR (1) | BRPI0917403A2 (hr) |
| CA (1) | CA2732071C (hr) |
| CY (1) | CY1115785T1 (hr) |
| DK (1) | DK2323647T3 (hr) |
| EA (1) | EA020237B1 (hr) |
| ES (1) | ES2524596T3 (hr) |
| HK (1) | HK1160790A1 (hr) |
| HR (1) | HRP20141149T1 (hr) |
| MX (1) | MX2011001419A (hr) |
| PL (1) | PL2323647T3 (hr) |
| PT (1) | PT2323647E (hr) |
| RS (1) | RS53694B1 (hr) |
| SI (1) | SI2323647T1 (hr) |
| SM (1) | SMT201500019B (hr) |
| WO (1) | WO2010015335A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826663A1 (en) | 2011-02-07 | 2012-08-16 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for diastolic congestive heart failure |
| BR112014015498A8 (pt) * | 2011-12-27 | 2017-07-04 | Koninklijke Philips Nv | método; sistema; e meio de armazenamento legível em computador não transitório |
| TWI725937B (zh) * | 2014-06-06 | 2021-05-01 | 美商海洋原料公司 | ω-３組成物、劑型及使用方法 |
| WO2019022436A2 (ko) * | 2017-07-27 | 2019-01-31 | 에리슨제약(주) | Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| CN1082909A (zh) | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
| US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| US5541225A (en) * | 1994-10-11 | 1996-07-30 | The General Hospital Corporation | α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia |
| IT1277953B1 (it) | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| AU2007322291A1 (en) * | 2006-10-13 | 2008-05-29 | Reliant Pharmaceuticals, Inc. | Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof |
-
2009
- 2009-07-23 ES ES09777388.1T patent/ES2524596T3/es active Active
- 2009-07-23 CA CA2732071A patent/CA2732071C/en active Active
- 2009-07-23 CN CN2009801356010A patent/CN102149376B/zh not_active Expired - Fee Related
- 2009-07-23 SI SI200931073T patent/SI2323647T1/sl unknown
- 2009-07-23 US US13/057,492 patent/US8592439B2/en active Active
- 2009-07-23 JP JP2011521456A patent/JP5563573B2/ja not_active Expired - Fee Related
- 2009-07-23 RS RS20140649A patent/RS53694B1/en unknown
- 2009-07-23 EA EA201100143A patent/EA020237B1/ru not_active IP Right Cessation
- 2009-07-23 DK DK09777388.1T patent/DK2323647T3/en active
- 2009-07-23 PL PL09777388T patent/PL2323647T3/pl unknown
- 2009-07-23 BR BRPI0917403A patent/BRPI0917403A2/pt not_active IP Right Cessation
- 2009-07-23 AU AU2009278317A patent/AU2009278317B2/en not_active Ceased
- 2009-07-23 KR KR1020117002755A patent/KR20110058775A/ko active Search and Examination
- 2009-07-23 WO PCT/EP2009/005347 patent/WO2010015335A1/en active Application Filing
- 2009-07-23 EP EP09777388.1A patent/EP2323647B1/en active Active
- 2009-07-23 PT PT97773881T patent/PT2323647E/pt unknown
- 2009-07-23 MX MX2011001419A patent/MX2011001419A/es active IP Right Grant
-
2012
- 2012-02-09 HK HK12101284.9A patent/HK1160790A1/xx not_active IP Right Cessation
-
2014
- 2014-11-25 HR HRP20141149AT patent/HRP20141149T1/hr unknown
- 2014-11-26 CY CY20141100980T patent/CY1115785T1/el unknown
-
2015
- 2015-01-21 SM SM201500019T patent/SMT201500019B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS53694B1 (en) | 2015-04-30 |
| AU2009278317A1 (en) | 2010-02-11 |
| SI2323647T1 (sl) | 2015-01-30 |
| US8592439B2 (en) | 2013-11-26 |
| EP2323647B1 (en) | 2014-09-10 |
| JP2011529928A (ja) | 2011-12-15 |
| CN102149376B (zh) | 2013-12-25 |
| BRPI0917403A2 (pt) | 2015-12-01 |
| US20110178111A1 (en) | 2011-07-21 |
| SMT201500019B (it) | 2015-03-05 |
| EP2323647A1 (en) | 2011-05-25 |
| JP5563573B2 (ja) | 2014-07-30 |
| EA201100143A1 (ru) | 2011-10-31 |
| WO2010015335A1 (en) | 2010-02-11 |
| DK2323647T3 (en) | 2014-12-08 |
| ES2524596T3 (es) | 2014-12-10 |
| HK1160790A1 (en) | 2012-08-17 |
| CY1115785T1 (el) | 2017-01-25 |
| CA2732071C (en) | 2018-02-13 |
| PT2323647E (pt) | 2014-12-16 |
| KR20110058775A (ko) | 2011-06-01 |
| AU2009278317A8 (en) | 2011-03-31 |
| MX2011001419A (es) | 2011-05-25 |
| WO2010015335A8 (en) | 2010-04-29 |
| EA020237B1 (ru) | 2014-09-30 |
| AU2009278317B2 (en) | 2014-12-18 |
| CN102149376A (zh) | 2011-08-10 |
| CA2732071A1 (en) | 2010-02-11 |
| PL2323647T3 (pl) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5069448B2 (ja) | 脳卒中再発予防用組成物 | |
| US7498359B2 (en) | Composition and method for preventing recurrence of stroke | |
| JP5809115B2 (ja) | 心血管イベント予防用製剤 | |
| HRP20180423T1 (hr) | Pripravci i postupci za smanjivanje triglicerida bez povećavanja razina ldl-c kod subjekta koji je na istovremenoj terapiji sa statinom | |
| JP5134916B2 (ja) | 心血管イベント発症予防用組成物 | |
| WO2009142242A1 (ja) | ハイリスク患者の心血管イベント予防用組成物 | |
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| CA3113177A1 (en) | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution | |
| HRP20141149T1 (hr) | Dugotrajno lijeäśenje simptomatske sräśane insuficijencije | |
| JP2013075926A (ja) | 多重リスク患者の心血管イベント発症予防用組成物 | |
| RU2018120726A (ru) | Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы | |
| RU2017126039A (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| CA2706270A1 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
| JP2008050367A5 (hr) | ||
| JP4005104B2 (ja) | 脳卒中再発予防用組成物 | |
| WO2009059717A3 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| JP4751257B2 (ja) | 心血管イベント発症予防用組成物 | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| RU2019139669A (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| US20110319467A1 (en) | Absorption Enhancement of Statins and Omega Fatty Acids |